18 Years
80 Years
Both
Gastroesophageal Varices Hemorrhage, Hepatocellular Carcinoma
Trial Information
Esophageal variceal bleeding is characteristic of high rebleeding rate and mortality. Thanks
to the recent advance of treatment for variceal bleeding such as non-selective beta blocker
(NSBB) added to endoscopic ligation further reduce rebleeding in cirrhotic patients, the
rebleeding rate and mortality has a marked reduction. However, hepatocellular carcinoma
(HCC) is a distinct group characteristic of very poor prognosis in patients with portal
hypertension when compared to those of liver cirrhosis only. Therefore, the investigators
design a study to randomize patients with HCC and acute variceal bleeding to endoscopic
treatment alone and combination with endoscopic treatment and NSBB. This is the two years
study.
Inclusion Criteria:
1. clinical diagnosis of HCC
2. endoscopically proven acute variceal bleeding
3. younger than 18 years old or older than 80 years old
Exclusion Criteria:
-Had a terminal illness of any major organ system,such as heart failure, kidney
failure,COPD
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Outcome Measure:
Rebleeding
Outcome Time Frame:
2 year
Safety Issue:
No
Authority:
Taiwan: Department of Health
Study ID:
V99C1-026;V100C-024
NCT ID:
NCT01451658
Start Date:
December 2009
Completion Date:
October 2012
Related Keywords:
- Gastroesophageal Varices Hemorrhage
- Hepatocellular Carcinoma
- Variceal bleeding
- portal hypertension
- hepatocellular carcinoma
- endoscopic variceal ligation
- non-selective beta-blocker
- rebleeding
- Carcinoma
- Hemorrhage
- Varicose Veins
- Carcinoma, Hepatocellular
- Esophageal and Gastric Varices
Name | Location |
|---|
